Mendus

Press release

Stockholm, Sweden, April 17, 2024

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that the Annual Report for 2023 has been published. The Annual Report is attached as a PDF and is available on the company’s corporate website: https://mendus.com/investors/financial-reports/

Mendus’ shareholders can request a printed copy of the Annual Report by contacting the company by e-mail, ir@mendus.com.

For more information, please contact:
Erik Manting, CEO
E-mail: ir@mendus.com

About Mendus AB (publ)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/